India Advises Drug Makers To Pass Along Excise Tax Cut
This article was originally published in PharmAsia News
India is advising drug makers that if they fail to pass along to consumers the reduction in the excise duty they had been charged, the government will consider a 4-5 percent reduction in drug prices. The advisory covers the entire drug industry, including drugs outside government control. The government is said to be considering meeting with drug industry associations before issuing a directive on prices. (Click here for more
You may also be interested in...
Gilead's remdesivir is first drug fully approved by FDA to treat COVID-19. Roche and Atea team up on an investigational direct acting antiviral while Moderna reaches the 30,000-patient enrollment target for its Phase III COVE study of the company's investigational mRNA vaccine.
From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.
Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.